Roquefort Therapeutics (LON:ROQ) Shares Up 8.2% – What’s Next?

Shares of Roquefort Therapeutics plc (LON:ROQ) traded up 8.2% during mid-day trading on Tuesday . The company traded as high as GBX 2 ($0.03) and last traded at GBX 1.84 ($0.02). 763,659 shares were traded during mid-day trading, a decline of 74% from the average session volume of 2,947,427 shares. The stock had previously closed at GBX 1.70 ($0.02).

Roquefort Therapeutics Stock Up 8.2 %

The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The business’s fifty day moving average price is GBX 1.92 and its 200 day moving average price is GBX 3.30. The company has a market capitalization of £2.34 million, a P/E ratio of -1.52 and a beta of 0.05.

Insiders Place Their Bets

In related news, insider Stephen Paul West acquired 400,000 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was purchased at an average cost of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,822.78). Corporate insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.